Hyperbaric Oxygen Therapy (HBOT) Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage policy describing when systemic HBOT is considered medically necessary and when topical HBOT or other uses are investigational; applies to providers and members covered by Blue Cross Blue Shield of North Carolina.
No material clinical or coverage changes in this revision.
Medical Necessity and Coverage Determinations
inv-01: Covered Indications
Systemic hyperbaric oxygen therapy may be considered medically necessary for the following conditions when clinically appropriate:
List taken directly from policy; each indication may have additional clinical context in policy guidelines.
inv-02: Selected non-covered/insufficient evidence indications
Summary statements on evidence for selected non-wound indications
Source: chunk 18
Source: chunk 18
Source: chunks 18 and 19
Source: chunks 18 and 19
Source: chunks 19 and 20
Topical hyperbaric oxygen therapy is investigational and is not covered by BCBSNC for all indications. In addition, hyperbaric oxygen therapy for conditions not explicitly listed as covered in this policy is considered investigational and therefore not covered.
Historically, the policy has maintained a comprehensive catalog of non-covered or investigational indications. Over time, items have been added, removed, or reclassified in the “When HBO Is Not Covered” sections (for example, the addition of a separate topical HBOT definition in 2007 and repeated listings of investigational indications such as autism spectrum disorders, early post-radiation treatment to reduce side effects, and other neurologic or non-wound conditions). The policy implementation history documents these changes across multiple updates dating back to the 2000s.
Any use of topical hyperbaric oxygen therapy remains classified as investigational and therefore not covered. Similarly, uses of HBOT that are not listed among the policy’s covered indications are considered investigational and will be denied.
For a number of other indications (for example, migraine, herpes zoster, fibromyalgia, multiple sclerosis, and some cancer-related uses), the policy frames the available data as insufficient to conclude that HBOT improves net health outcomes. These conditions are described in the policy’s summary of evidence as having limited or inconsistent RCT and systematic review data, and therefore are not supported for coverage based on current evidence.
Service Codes and Coding-Related Criteria
| No codes listed |
| No codes listed |
Prior Authorization, Documentation, and Billing Guidance
Prior authorization required for systemic HBOT; topical HBOT not covered
BCBSNC requires prior authorization for systemic hyperbaric oxygen therapy when medical necessity criteria in this policy are met; topical hyperbaric oxygen therapy is investigational and is not covered.
Use listed service codes — reimbursement contingent on medical necessity
Report applicable service codes on claims but note that inclusion of a code does not guarantee reimbursement; BCBSNC may require medical records to determine medical necessity.
Attempt adequate standard wound therapy first for diabetic foot ulcers
For non-healing diabetic lower-extremity wounds, systemic HBOT is appropriate only after an adequate course of standard wound therapy with no measurable signs of healing after 30 days.
- Policy threshold: no measurable signs of healing after 30 days of an adequate course of standard wound therapy.
- Guideline context: some professional guidelines consider lack of >50% wound area reduction after 4 weeks (or 4–6 weeks) as failure of conservative therapy.
Confirm coverage criteria and obtain prior authorization before treatment
Confirm eligibility criteria and obtain prior authorization per BCBSNC procedures before initiating HBOT; ensure billing codes and documentation align with the medical necessity criteria in the policy.
- Verify the patient meets the specific covered-indication criteria (e.g., Wagner grade ≥3 for diabetic lower-extremity wounds).
- Submit prior authorization requests with supporting documentation tied to the listed service codes.
Document diagnosis, wound characteristics, and prior standard therapy
Clinical records should document the diagnosis, wound characteristics (including Wagner grade for diabetic foot ulcers), and prior standard wound therapy with lack of measurable healing where applicable.
- Document wound classification (Wagner grade) for diabetic foot ulcers.
- Document dates and details of the adequate course of standard wound therapy and objective evidence of no measurable healing after the specified interval.
When submitting records, include all specific clinical information (letters alone insufficient)
If BCBSNC requests medical records, include full clinical details; letters of support or explanation may be helpful but are not sufficient unless they contain all specific information needed for a medical necessity determination.
- Provide complete records showing wound status, treatment timeline, objective measures of healing, and relevant imaging or operative notes as applicable.
Topical HBOT and other non-listed uses are investigational and may be denied
Topical hyperbaric oxygen therapy is considered investigational and is not covered; any HBOT use not listed among the policy’s covered indications is investigational and may be denied.
- Do not seek coverage for topical HBOT—claims for investigational uses are subject to denial under this policy.
Medical records may be requested to support medical necessity despite code inclusion
BCBSNC may request medical records to determine medical necessity; inclusion of a listed service code does not ensure payment without supporting documentation.
- Be prepared to submit the clinical records that demonstrate the specific policy criteria are met when requested.
Key Terms and Clinical Definitions
Clinical Background and Rationale
Hyperbaric oxygen therapy may be delivered systemically or topically. Systemic HBOT involves enclosing an individual in a pressure chamber and providing oxygen at pressures greater than atmospheric so that oxygen is carried systemically via the circulation. By contrast, topical HBOT delivers 100% oxygen directly to an open moist wound within an appliance that encloses only the wound area at pressures slightly above atmospheric. The policy notes that systemic HBOT treats systemic illnesses (for example, gas embolism and carbon monoxide poisoning) while topical delivery is limited to local wound exposure and is considered a distinct, investigational approach.
Policy Development and Review History
Definition of Topical Hyperbaric Oxygen Therapy added to Description; topical HBOT noted as distinct from systemic HBOT and a separate topical HBOT policy referenced; Wagner classification added to Covered section; code A4575 deleted; effective date 2007-08-13.
Indications reorganized to numbered list and expanded: soft-tissue radiation necrosis and osteoradionecrosis plus pre/post dental surgery for irradiated jaw added to When Covered; related deletions from When Not Covered.
Routine biennial review with Specialty Matched Consultant Advisory Panel; no change to policy statement.
Added early post-radiation treatment to reduce RT side effects and autism spectrum disorders to the non-covered indications; notification for 2010-12-21 effective date.
Acute carbon monoxide poisoning and chronic refractory osteomyelitis added to When HBO Is Covered; Policy Guidelines updated.
Policy statement amended to state Topical Hyperbaric Oxygen Therapy is considered investigational and is not covered; several indications added to non-covered list and HCPCS codes A4575 and E0446 added to Billing/Coding.
Added investigational indications including bisphosphonate-related osteonecrosis of the jaw, motor dysfunction associated with stroke, herpes zoster and vascular dementia to When Not Covered.
Added HCPCS code G0277 to Billing/Coding effective 2015-01-01; Specialty Matched Consultant Advisory Panel review in January 2014 noted no policy change.
When Covered section updated to include chronic refractory osteomyelitis, compromised skin grafts or flaps, necrotizing soft-tissue infections, severe anemia, idiopathic sudden sensorineural hearing loss, intracranial abscesses, acute thermal burns, avascular insufficiencies including central retinal artery occlusion and selected problem wounds.
Policy name changed from 'Hyperbaric Oxygen Pressurization' to 'Hyperbaric Oxygen Therapy'; Description and references updated.
Specialty Matched Consultant Advisory Panel review; no change to policy statement.
Specialty Matched Consultant Advisory Panel review; no change to policy statement.
Description and Policy Guidelines sections updated after Specialist Advisory Panel review; no change to policy statement.
References and Policy Guideline section updated following advisory panel review; no change to policy statement.
Policy Guidelines and Description of Service updated with added references; no change to policy statement.
Specialty Matched Consultant Advisory Panel review and references updated; no change to policy statement.
References updated; Specialty Matched Consultant Advisory Panel and Medical Director reviews in October 2021 noted no change to policy statement.
Minor updates to policy guidelines and references updated after advisory panel and medical director reviews in October 2022; no change to policy statement.
Regulatory status updated and wording changed from 'patients' to 'individuals' in coverage criteria; references updated after October 2023 reviews; no change to policy statement.
References updated and 'avascular necrosis (aseptic osteonecrosis)' added to When Covered based on updated UHMS guidelines; policy guidelines updated following October 2024 reviews.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.